Comparison of an aggressive (U.S.) and a less aggressive (Canadian) policy for cholesterol screening and treatment.

OBJECTIVE To determine the point at which adverse quality-of-life effects engendered by an aggressive cholesterol-lowering strategy dictate the use of a less aggressive approach. DESIGN Decision analysis was used to compare the effects of the National Cholesterol Education Program (NCEP) guidelines, an aggressive program, with those of the Canadian Task Force on the Periodic Health Examination (CTF) guidelines, a more conservative program. Quality-adjusted life expectancy was calculated for a theoretical cohort of middle-aged men treated according to each program using Markov cohort analysis. MEASUREMENTS Guidelines were applied to the population of the Lipid Research Clinics Coronary Primary Prevention Trial (LRC-CPPT), under the assumption that cholesterol levels had the distribution of the age- and sex-matched general population. Outcomes were calculated using a three-state (health, coronary heart disease, and death) Markov model. State transition probabilities were calculated using bivariate (age and cholesterol) proportional hazards and logistic regression functions. MAIN RESULTS The result was a "toss-up"; the number of expected quality-adjusted life years was similar for both programs at all time intervals, although the conservative program was consistently slightly favored. The result was very sensitive to the disutility of dietary therapy (threshold value, 0.0014 compared with the baseline estimate of 0.02) but was also affected by the time frame of the analysis and the rate at which adverse effects of treatment decline. CONCLUSIONS Even small disutilities associated with treatment may outweight the benefits of aggressive cholesterol-lowering strategies. Research should be directed toward measuring these disutilities and finding ways to reduce their size. Incorporation of the disutility of treatment into policy formulation may result in less interventionist and less costly policies.

[1]  G. Oster,et al.  Cost-effectiveness of antihyperlipemic therapy in the prevention of coronary heart disease. The case of cholestyramine. , 1987, JAMA.

[2]  A. Menotti,et al.  Coronary risk factors and survival probability from coronary and other causes of death. , 1987, American journal of epidemiology.

[3]  S. Leeder,et al.  A cost‐effectiveness analysis of alternative strategies for the prevention of heart disease , 1988, The Medical journal of Australia.

[4]  R B Haynes,et al.  Increased absenteeism from work after detection and labeling of hypertensive patients. , 1978, The New England journal of medicine.

[5]  Joseph S. Pliskin,et al.  Utility Functions for Life Years and Health Status , 1980, Oper. Res..

[6]  H. Hart,et al.  Considerations of mortality in certain chronic diseases. , 1966, Annals of internal medicine.

[7]  B. Kinosian,et al.  Cutting into cholesterol. Cost-effective alternatives for treating hypercholesterolemia. , 1988, JAMA.

[8]  G W Torrance,et al.  Utility approach to measuring health-related quality of life. , 1987, Journal of chronic diseases.

[9]  Daniel Steinberg,et al.  Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. , 1988, Archives of internal medicine.

[10]  Moss Jm Psychosocial consequences of labelling in hypertension. , 1981 .

[11]  W. Browner Estimating the impact of risk factor modification programs. , 1986, American journal of epidemiology.

[12]  R. Lefebvre,et al.  Labeling of participants in high blood pressure screening programs. Implications for blood cholesterol screenings. , 1988, Archives of internal medicine.

[13]  D H Blankenhorn,et al.  Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. , 1987, JAMA.

[14]  J. Huttunen,et al.  Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. , 1987, The New England journal of medicine.

[15]  S. Pauker,et al.  The Markov Process in Medical Prognosis , 1983, Medical decision making : an international journal of the Society for Medical Decision Making.

[16]  M. Alderman,et al.  Hypertension control at the work site. , 1976, Journal of occupational medicine. : official publication of the Industrial Medical Association.

[17]  A. Komaroff,et al.  Cholesterol reduction and life expectancy. A model incorporating multiple risk factors. , 1987, Annals of internal medicine.

[18]  J. C. Christiansen,et al.  Impact of national guidelines for cholesterol risk factor screening. The Framingham Offspring Study. , 1989, JAMA.

[19]  C. Naylor,et al.  Asymptomatic hypercholesterolemia: a clinical policy review. , 1990 .

[20]  D. Levy,et al.  Cholesterol and mortality. 30 years of follow-up from the Framingham study. , 1987, JAMA.

[21]  B. Lo,et al.  Choice and use of blood lipid tests. An epidemiologic perspective. , 1983, Archives of internal medicine.

[22]  G. Torrance,et al.  The utility of different health states as perceived by the general public. , 1978, Journal of chronic diseases.

[23]  A. Brett,et al.  Treating hypercholesterolemia. How should practicing physicians interpret the published data for patients? , 1989, The New England journal of medicine.